Ethosuximide (All indications)

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Samrén (Ethosuximide), 1999 Dean (Ethosuximide), 2002 Kaaja (Ethosuximide), 2003 Morrow (Ethosuximide) (Controls unexposed, sick), 2006 Bànhidy (Ethosuximide), 2011 Källén (Ethsuximide) (Controls unexposed, NOS) (Indications NOS), 2013 Vajda (Ethosuximide) (Controls unexposed, sick), 2019 Battino (Ethosuximide) (Epilepsy), 2024 82.56[0.97; 6.76]49,67664not evaluable Major congenital malformations Samrén (Ethosuximide), 1999 Dean (Ethosuximide), 2002 Kaaja (Ethosuximide), 2003 Morrow (Ethosuximide) (Controls unexposed, sick), 2006 Bànhidy (Ethosuximide), 2011 Källén (Ethsuximide) (Controls unexposed, NOS) (Indications NOS), 2013 Vajda (Ethosuximide) (Controls unexposed, sick), 2019 Battino (Ethosuximide) (Epilepsy), 2024 82.76[1.01; 7.56]49,67064not evaluable Congenital heart defects Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 16.21[0.32; 122.15]412not evaluable Hypospadias Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 14.28[0.23; 80.64]612not evaluable Microcephaly / Small head circumference for gestational age Christensen (Ethosuximide) (All indications) (Controls unexposed, general population), 2024 11.54[0.09; 26.28]134,02311not evaluable Neural Tube Defects Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 118.71[0.72; 484.16]112not evaluable Digestive system anomalies Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 17.99[0.39; 163.81]312not evaluable Eye defects Dean (Ethosuximide), 2002 15.33[0.29; 97.49]72not evaluable Limb defects Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 111.21[0.51; 246.80]212not evaluable Minor congenital malformations Dean (Ethosuximide), 2002 12.20[0.19; 25.52]64not evaluable Oro-facial clefts Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 118.71[0.72; 484.16]112not evaluable Polydactyly 0----- Growth parameters and prematurity Low birth weight (< 2500g) Kilic (Ethosuximide) (Controls unexposed, sick) (Mixed indications), 2014 120.14[0.40; 1017.27]2491not evaluable Preterm (< 37 weeks) Kilic (Ethosuximide) (Controls unexposed, sick) (Mixed indications), 2014 112.81[0.25; 646.50]3831not evaluable Small for gestational age (weight) Kilic (Ethosuximide) (Controls unexposed, sick) (Mixed indications), 2014 17.87[0.16; 397.17]5941not evaluable Neonatal disorders Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation 0----- Intrauterine deaths Intrauterine deaths (as a whole or unspecified) Vajda a (Ethosuximide) (Controls unexposed sick) (Epilepsy), 2024 1----- Neuro-developmental disorders Neuro-developmental disorders (as a whole) Dean (Ethosuximide), 2002 18.50[0.44; 163.89]52not evaluable0.0100.01.0

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons